The total return over the past 12 months is -53.37% vs. +16.94% for the S&P 500. So far it's up -36.96% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (53.37%) | (25.43%) | (30.14%) | (14.91%) | N/A | N/A |
| Total Return CAGR | (53.37%) | (25.43%) | (30.14%) | (14.91%) | N/A | N/A |
| Revenue CAGR | +17.50% | +21.18% | +14.81% | +190.11% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Ultragenyx Pharmaceutical Inc. (RARE)
| Year | Start price | End price | RARE Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $23.00 | $14.50 | (36.96%) | +14.51% | (51.47%) |
| 2025 | $42.07 | $23.00 | (45.33%) | +17.72% | (63.05%) |
| 2024 | $47.82 | $42.07 | (12.02%) | +24.89% | (36.91%) |
| 2023 | $46.33 | $47.82 | +3.22% | +26.19% | (22.97%) |
| 2022 | $84.09 | $46.33 | (44.90%) | (18.17%) | (26.73%) |
| 2021 | $138.43 | $84.09 | (39.25%) | +28.74% | (67.99%) |
| 2020 | $42.71 | $138.43 | +224.12% | +18.37% | +205.75% |
| 2019 | $43.48 | $42.71 | (1.77%) | +31.22% | (32.99%) |
| 2018 | $46.38 | $43.48 | (6.25%) | (4.56%) | (1.69%) |
| 2017 | $70.31 | $46.38 | (34.03%) | +21.70% | (55.73%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
